ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions
  • 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship
  • ACR Late-breaking Abstract Poster Presentations
  • ACR Late-breaking Abstracts Session
  • ACR Plenary Session I: Discovery 2014
  • ACR Plenary Session II: Discovery 2014
  • ACR Plenary Session III: Discovery 2014
  • ACR/ARHP Combined Abstract Session: Epidemiology and Public Health
  • ACR/ARHP Combined Abstract Session: Pediatric Rheumatology
  • ACR/ARHP Combined Abstract Session: Rehabilitation
  • Antiphospholipid Syndrome
  • B cell Biology and Targets in Autoimmune Disease
  • B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases
  • B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases
  • Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis
  • Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation
  • Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis
  • Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling
  • Clinical Practice/Patient Care
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II
  • Education
  • Education (ACR)
  • Education (ARHP): Education/Community Programs
  • Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment
  • Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes
  • Epidemiology and Public Health (ARHP)
  • Epidemiology and Public Health (ARHP): Epidemiology and Public Health
  • Epidemiology and Public Health I: Drug and Vaccine Safety
  • Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more
  • Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus
  • Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis
  • Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More
  • Epidemiology/Public Health
  • Exemplary Abstracts
  • Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives
  • Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives
  • Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus
  • Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus
  • Genetics, Genomics and Proteomics
  • Genetics, Genomics and Proteomics I
  • Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity
  • Genetics, Genomics and Proteomics II
  • Genetics, Genomics and Proteomics II: Genetics of Autoimmunity
  • Health Disparities/Social Determinants of Health
  • Health Services Research
  • Health Services Research (ARHP): Health Services Research
  • Health Services Research: Improving Clinical Practice
  • Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease
  • Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI)
  • Imaging of Rheumatic Diseases: Ultrasound
  • Imaging of Rheumatic Diseases: Various Imaging Techniques
  • Imaging of Rheumatic Diseases: X-ray, MRI and CT
  • Infections, Infection-related Biomarkers and Impact of Biologic Therapies
  • Innate Immunity and Rheumatic Disease
  • Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors
  • Innate Immunity and Rheumatic Disease: Signaling Mechanisms
  • Innovations in Rheumatologic Care
  • Metabolic and Crystal Arthropathies I: Clinical Aspects
  • Metabolic and Crystal Arthropathies II: Mechanisms of Disease
  • Metabolic and Crystal Arthropathies: Clinical Aspects
  • Metabolic and Crystal Arthropathies: Mechanisms of Disease
  • Miscellaneous Rheumatic and Inflammatory Diseases
  • Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease
  • Muscle Biology, Myositis and Myopathies
  • Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy
  • Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype
  • Orthopedics, Low Back Pain and Rehabilitation
  • Osteoarthritis
  • Osteoarthritis - Clinical Aspects I: Imaging in Osteoarthritis
  • Osteoarthritis - Clinical Aspects II: Osteoarthritis Risk Factors and Therapies
  • Osteoarthritis - Clinical Aspects: Epidemiology and Pathogenesis
  • Osteoarthritis - Clinical Aspects: Imaging and Biomechanics
  • Osteoarthritis - Clinical Aspects: Therapeutics
  • Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety
  • Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis
  • Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes
  • Pain: Basic and Clinical Aspects
  • Pain: Basic and Clinical Aspects I
  • Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases
  • Pediatric Rheumatology - Pathogenesis and Genetics
  • Pediatric Rheumatology – Clinical and Therapeutic Aspects (ARHP): Pediatrics
  • Psychology/Social Sciences (ARHP)
  • Quality Measures and Quality of Care
  • Rehabilitation Sciences (ARHP)
  • Research Methodology (ARHP)
  • Rheumatoid Arthritis - Animal Models
  • Rheumatoid Arthritis - Animal Models I
  • Rheumatoid Arthritis - Animal Models II
  • Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality
  • Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches
  • Rheumatoid Arthritis - Clinical Aspects (ARHP): Clinical Practice/Patient Care
  • Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk
  • Rheumatoid Arthritis - Clinical Aspects II: Remission and De-escalation of Therapy
  • Rheumatoid Arthritis - Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery
  • Rheumatoid Arthritis - Clinical Aspects IV: Promising Biomarkers
  • Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes
  • Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions
  • Rheumatoid Arthritis - Clinical Aspects VII: New Aspects of Monitoring Disease
  • Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis - Late in Development
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis
  • Sjogren's Syndrome I: Clinical Perspectives
  • Sjogren's Syndrome II: Insights into Pathophysiology
  • Sjogren's Syndrome: Clinical Science
  • Sjogren's Syndrome: Pathophysiology
  • Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I
  • Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II
  • Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III
  • Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology
  • Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology: From Genes to Cytokines
  • Spondyloarthropathies and Psoriatic Arthritis I - Novel Treatments Axial Spondyloarthritis
  • Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis
  • Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis
  • Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis
  • Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment
  • Spondyloarthropathies and Psoriatic Arthritis VI - Imaging and Biomarkers
  • Systemic Lupus Erythematosus - Animal Models
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Cardiovascular Disease and Pregnancy
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II
  • T cell Biology and Targets in Autoimmune Disease
  • T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity
  • T cell Biology in Rheumatoid Arthritis and Other Arthritis
  • Vasculitis
  • Vasculitis I
  • Vasculitis II
  • Vasculitis III
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology